Protocol No.: D8531C00002

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Principal Investigator
Kurian, Sobha
Age Group
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Emily Hawkins, BSN
Research Nurse
Phone: +1 304-293-7375

View on